NDAORALCAPSULE
Approved
Nov 2004
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
ANTARA (MICRONIZED) (fenofibrate) by Molecular Devices is peroxisome proliferator-activated receptor alpha agonists [moa]. Approved for dyslipidemia, hypertriglyceridemia, hypercholesterolemia and 1 more indications. First approved in 2004.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANTARA (micronized fenofibrate) is an oral fibrate that activates peroxisome proliferator-activated receptor alpha (PPAR-α) to treat dyslipidemia, hypertriglyceridemia, and hypercholesterolemia. It works by enhancing triglyceride clearance and modulating lipid metabolism in the liver. The micronized formulation improves bioavailability compared to standard fenofibrate.
Peak7.1 years to LOE
Product is at peak maturity with stable market position; brand teams likely focused on lifecycle extension and managed care negotiations rather than growth initiatives.
Mechanism of Action
Peroxisome Proliferator-activated Receptor alpha Agonists
Pharmacologic Class:
Peroxisome Proliferator Receptor alpha Agonist
Indications (4)
Worked on ANTARA (MICRONIZED) at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.